An analytical method for the quantitation of amifloxacin, 6-fluoro-1,4-dihydro-l-(methylamino)-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, in plasma and urine has been developed. The method involves extraction with chloroform, back-extraction into 0.1 M sodium hydroxide, and subsequent analysis by reverse-phase high-pressure liquid chromatography with UV detection. The precision of the assay calculated as the overall standard deviation was ±4.9% in plasma and ±+1.1% in urine. The range of mean percent differences from the nominal values was used as an estimate of accuracy and was 93.6 to 103% of the nominal values in plasma and 95.2 to 107% of the nominal values in urine. The minimum quantifiable levels were 0.032 ,ug/ml in plasma and 2.7 ,ug/ml in urine. The methods were employed in a pharmacokinetic analysis of amifloxacin after intravenous administration to rhesus monkeys. The decline in drug plasma levels was described by a biexponential process with mean rates of 8.4 h-1 and 0.32 h-1 with corresponding half-lives of ca. 5 min and 2.2 h. Amifloxacin was rapidly excreted, with ca. 53% of the dose appearing in the urine within 48 h after medication. The mean renal clearance ± standard deviation was 4.4 ± 1.0 ml * kg-l * min'1 and is compatible with passive glomerular filtration in this species.
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Amifloxacin (formerly WIN 49375), 6-fluoro-1,4-dihydro-1-(methylamino)-7 -(4-methyl-1-piperazinyl)-4 -oxo-3 -quinolinecarboxylic acid (Fig. 1) , is a member of the fluoroquinolone carboxylic acid class and most closely resembles pefloxacin (6) . The compound is a potent antimicrobial agent with a broad spectrum of activity against gram-negative organisms and potential for treating some gram-positive infections (N. Jacobus, F. P. Tally, and M. Barza, Program Abstr. Intersci, Conf. Antimicrob. Agents Chemother. 23rd, Las Vegas, Nev., abstr. no. 702, 1983 ). The compound is well absorbed and has demonstrated oral efficacy in animals. The present report details the analytical methods for the quantitation of amifloxacin in plasma and urine and uses these methods to estimate pharmacokinetic parameters after intravenous (i.v.) administration to rhesus monkeys.
MATERIALS AND METHODS
Reagents. Amifloxacin, its principle metabolites, and the internal standard (see Fig. 1 ) were synthesized at SterlingWinthrop Research Institute and used without further purification. Acetonitrile was purchased from Fisher Scientific Co. as high-pressure liquid chromatography grade, and tetrabutyl ammonium phosphate was purchased from Eastman Kodak Co. All chemicals were reagent grade or better. Water was redistilled and purified with a Barnstead Organicpure system. Preparation of standards. For calibration of the chromatographic system, stock solutions of the drug were prepared in 0.01 M sodium hydroxide, and portions were added to either 1.0 ml of human plasma (oxalate-fluoride anticoagulant) or to 1.0 ml of human urine. Duplicate standards were prepared at seven concentrations from 0.0 to 5.0 ,ug/ml in plasma and * Corresponding author. from 0.0 to 100 pg/ml in urine. Stock solutions and standards were freshly prepared for each analytical run.
Extraction. To each 1.0 ml of plasma standard or sample was added 50 ,ul of the internal standard solution (20 K.g/ml in 0.01 M sodium hydroxide) and 0.3 ml of 1.0 M sodium phosphate buffer (pH 6.6). Seven milliliters of chloroform was added and mixed for 10 min, and the layers were separated by centrifugation. The chloroform layer was backextracted with 0.6 ml of 0.1 M sodium hydroxide, and the layers again were separated by centrifugation. To 0.3 ml of the aqueous layer was added 30 ,ul of 1 N sulfuric acid and 100 ,ul of mobile phase (see below).
To each urine standard or sample was added 100 l.l of the internal standard (100 ,ug/ml in 0.01 M sodium hydroxide) and 0.3 ml of 1.0 M sodium phosphate buffer (pH 6.6). Eight milliliters of chloroform was added, followed by thorough mixing and centrifugation to separate the aqueous and organic phases. Four milliliters of the organic phase was transferred to a separate tube and back-extracted with 0.80 ml of 0.1 N sodium hydroxide. -For injection into the chromatographic system, 0.2 ml of the aqueous phase was mixed with 20 RI of 1 N sulfuric acid and 300 p.l of the mobile phase.
Chromatography Urine samples were collected,with a Foley catheter over specified time intervals. At the end of each collection period, the bladder of the animal was rinsed with 5 ml of water, and the rinse was saved separately. After 12 h, urine samples were collected in metabolism cages. Both urine and rinse samples were stored in the laboratory freezer until analyzed.
RESULTS AND DISCUSSION In view of the analytical methods for several related compounds (1, 2, 7, 8, 10), analysis of amifloxacin was developed by high-pressure liquid chromatography. We observed the best separation by reverse-phase chromatography in the presence of the ion-pairing reagent tetrabutyl ammonium phosphate. Computer-generated chromatograms of extracts from human samples containing added drug are shown in Fig. 2 . Comparisons of Fig. 2A with 2B (plasma) and Fig. 2C with 2D (urine) demonstrates the lack of interfering absorbance by endogenous substances within the retention time of interest. The piperazinyl N-desmethyl metabolite of amifloxacin has a retention time of ca. 9.7 min in the system (Fig. 1) . A second major metabolite in some species, the piperazinyl N-oxide, is not extracted by the described procedure (Fig. 1) (5) .
To determine extraction efficiencies, stock solutions of the drug were injected into the chromatographic system, and the peak heights were used to calculate a least-squares regression line. Triplicate plasma and urine samples were prepared at multiple concentrations and extracted, and the concentration of the extract was determined from the above regression. The overall mean recovery of amifloxacin from plasma ± the standard error of the mean was 93.8 ± 4.9% (n = 11). For urine the mean recovery was 82.0 + 2.2% (n = 12).
Extraction efficiencies of the internal standard were determined at 1.0 ,±g/ml in plasma and 10 ,ug/ml in urine; the mean recoveries were 93 and 91%, respectively.
Linearity was observed for plasma standards between 0.10 and 5.0 ,g/ml (RJ2 > 0.999) with the mnean minimum pLg/ml. Lower MQL values cotuld be obtained if the standard curve were run at a lower concentration; however, observed urine levels were generally quite high.
To determine the reliability, precision, and accuracy of the assay, samples analyzed under single blind conditions were prepared by the addition of appropriate amounts of amifloxacin stozk solution to 1.0 ml of the biological medium. Two sets of samples were prepared, each set consisting of triplicate samples at each of five concentrations (including zero). One set was analyzed immediately after preparation, and the second set was frozen for several days before being analyzed. A summary of the results of these assays are shown in Table 1 The analytical methods were used to ascertain the pharmacokinetic parameters of amifloxacin after a 10-mg (base equivalent) per kg i.v. injection to rhesus monkeys. In plasma there was a rapid decline in drug levels for the first 30 ,min, at which time the mean plasma level was 6.73 ,g/ml. Thereafter, drug levels declined' more slowly and dropped below detectable levels some time after 12 h. This is represented graphically in Fig. 3 4 . About 20% of the dose was excreted within the first 2 h and ca. 53% of the dose was excreted within 48 h.
Renal clearance rates were also calculated for time periods between 0 and 12 h from the slope of the excretion rate as a function of the plasma concentration at the midpoint of the collection interval. The mean clearance + standard deviation was 4.4 ± 1.0 ml * min-1 * kg-1 and is compatible with passive glomerular filtration of the drug in this species (11) . 
